Search

Your search keyword '"Allergan PLC -- Product development"' showing total 9 results
Start Over Descriptor "Allergan PLC -- Product development" Journal mena report
9 results on '"Allergan PLC -- Product development"'

1. Ireland : Allergan Announces Positive Phase 3 Achieve I Trial Results For Ubrogepant Published In The New England Journal Of Medicine

Subjects
Allergan PLC -- Product development, Migraine -- Drug therapy, Clinical trials, Pharmaceutical industry -- Product development, Business, international, Ubrelvy (Medication) -- Product development
Abstract

Allergan plc announced that positive results from ACHIEVE I (UBR-MD-01), a robust Phase 3 clinical trial evaluating the efficacy, safety and tolerability of ubrogepant, have been published in the December [...]

Published
2019

2. Ireland : Allergan Announces Positive Phase 3 Achieve Ii Trial Results For Ubrogepant Published In The Journal Of The American Medical Association

Subjects
Allergan PLC -- Product development, Clinical trials, Pharmaceutical industry -- Product development, Migraine -- Drug therapy, Business, international
Abstract

Allergan plc announced that positive results from ACHIEVE II (UBR-MD-02), a pivotal Phase 3 clinical trial evaluating the efficacy, safety and tolerability of ubrogepant, have been published in the November [...]

Published
2019

3. Ireland : Allergan Announces Positive Topline Phase 3 Clinical Data for Bimatoprost SR (Sustained-Release) Implant for IOP Lowering in Patients with Open-Angle Glaucoma or Ocular Hypertension

Subjects
Allergan PLC -- Product development, Clinical trials, Ophthalmic agents -- Product development, Hypertension -- Care and treatment, Pharmaceutical industry -- Product development, Open-angle glaucoma -- Care and treatment, Business, international
Abstract

Allergan plc, a leading global pharmaceutical company, today announced the release of new topline clinical trial data on Bimatoprost SR, the first-in-class sustained-release, biodegradable implant for the reduction of intraocular [...]

Published
2018

4. Ireland : Allergan's Oral CGRP Receptor Antagonist Atogepant Demonstrates Robust Efficacy and Safety in Episodic Migraine Prevention in a Phase 2b|3 Clinical Trial

Subjects
Allergan PLC -- Product development, Clinical trials, Pharmaceutical industry -- Product development, Migraine, Business, international
Abstract

Allergan plc, a leading global pharmaceutical company, announced positive results from CGP-MD-01, a Phase 2b/3 clinical trial evaluating the efficacy, safety, and tolerability of orally administered atogepant. All active treatment [...]

Published
2018

5. Ireland : Allergan Presented New Phase 3 Data of Ulipristal Acetate in Women with Uterine Fibroids at the American Society for Reproductive Medicine Annual Congress

Subjects
Allergan PLC -- Product development, Clinical trials -- Analysis, Uterine fibroids -- Analysis, Pharmaceutical industry -- Product development -- Analysis, Women -- Analysis, Acetates -- Product development -- Analysis, Business, international
Abstract

Allergan plc, presented new analyses of VENUS II, the second of two pivotal Phase 3 clinical trials evaluating the efficacy and safety of ulipristal acetate (UPA), an investigational drug for [...]

Published
2017

6. United States : Amgen And Allergan Present Phase 3 Data On Biosimilar Trastuzumab Candidate ABP 980 At The European Society For Medical Oncology 2017 Congress

Subjects
Allergan PLC -- Product development, Pharmaceutical industry -- Product development, Associations, Trastuzumab -- Product development, Business, international, European Society for Medical Oncology
Abstract

Amgen and Allergan plc today announced data from a Phase 3 study evaluating the efficacy and safety of ABP 980, a Herceptin (trastuzumab) biosimilar, compared with the originator product in [...]

Published
2017

7. Ireland : FDA approves Allergan's sNDA for AVYCAZ (ceftazidime and avibactam) to include new Phase III data in Patients with Complicated Urinary Tract Infections (cUTI), Including Pyelonephritis

Subjects
United States. Food and Drug Administration, Allergan PLC -- Product development, Pyelonephritis, Urinary tract infections, Pharmaceutical industry -- Product development, Drug approval, Business, international, Avycaz (Medication)
Abstract

Allergan plc, a leading global pharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has approved the company's supplemental New Drug Application (sNDA) to update the label for [...]

Published
2017

8. Ireland : Amgen And Allergan Announce Top-Line Results From Phase 3 Study Evaluating ABP 980 Compared With Trastuzumab In Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer

Subjects
Allergan PLC -- Product development, Epidermal growth factors -- Comparative analysis, Pharmaceutical industry -- Product development -- Comparative analysis, Breast cancer -- Care and treatment -- Comparative analysis, Trastuzumab -- Product development -- Comparative analysis, Business, international
Abstract

Amgen and Allergan plc today announced results from a Phase 3 study evaluating efficacy and safety of ABP 980 compared with trastuzumab in patients with human epidermal growth factor receptor [...]

Published
2016

9. United States : USFDA approves Allergan's NDA filing for Oxymetazoline HCI cream 1.0%

Subjects
United States. Food and Drug Administration, Allergan PLC -- Product development, Pharmaceutical industry -- Product development, Drug approval, Business, international
Abstract

Allergan plc has announced that the U.S. Food and Drug Administration (FDA) has approved for standard review the New Drug Application (NDA) filing for oxymetazoline HCl cream 1.0%, an investigational [...]

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results